Breaking up Sitting With a Treadmill Desk in Office Workers

April 16, 2019 updated by: Daniel Bailey, University of Bedfordshire

Breaking up Prolonged Sitting Time in Office Workers With Light-intensity Walking: A Pilot Randomized Controlled Trial

Sitting for long uninterrupted periods of time can increase risk of heart disease, diabetes and early death, even if you take part in the United Kingdom government guidelines for physical activity of 21/2 hours per week of exercise. Effective interventions to reduce the risk of these diseases are therefore needed. The aim of this study is to examine the effects of regularly breaking up sitting time with light intensity treadmill desk walking among office workers on health markers, sitting time and physical activity. If using a treadmill desk leads to benefits in these disease risk markers then this could be an effective strategy to improve employee health in the workplace.

Participants will be randomly assigned to the intervention group or the control group. After baseline activity and health measures, they will take part in the study for 4 weeks.

Intervention group: Participants will have a treadmill desk placed in their office or a nearby location and will be asked to walk while working on the treadmill desk continuously for 20 minutes at a self-selected slow pace each hour for a minimum of 6 hours per shift. There will be one treadmill desk between 2-3 people.

Control group: Participants will be asked to work as usual at their regular workstation with no changes in their physical activity and dietary habits.

Sitting time and physical activity will be measured at baseline and during the last week f the intervention. A range of health and psychological measures will be taken at baseline and post-intervention.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Withdrawn

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

14 years to 61 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • adults aged 18-65 years who work for shifts lasting ≥ 6 h and spend ≥ 75% of this time sitting at their desk
  • work a minimum of 3 days per week

Exclusion Criteria:

  • the presence of any known blood borne disease
  • self-reported diagnosed diabetes
  • physical activity contraindications
  • pregnancy
  • any major injury or illness, tobacco use, or any other health issue that my limit the participant in carrying out the required activity bouts.
  • any planned absence from their office for more than one week during the 4 week study period.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
No Intervention: Control
The control group will continue to work as usual at their regular workstations.
Experimental: Intervention
A shared treadmill workstation will be installed in participating offices, or in a nearby location in case there is no space to fit the workstation in the office, enrolled to this group. Within the intervention group there will be a maximum allocation of two participants per treadmill desk. The participants in the intervention group will be asked to interrupt their sitting with 20 minutes of self-selected light-intensity walking at a speed of 1-4 km/h each hour for a minimum of 6 hours per shift to accumulate a total of 2 hours of light-intensity activity per work day.
Behavioral: Treadmill desk walking
See intervention arm description

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Change in Workplace sitting time
Time Frame: Baseline and week 4 of intervention
This will be objectively measured using an activpal thigh worn activity monitor
Baseline and week 4 of intervention

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Change in Workplace stepping
Time Frame: Baseline and week 4 of intervention
This will be objectively measured using an activpal thigh worn activity monitor
Baseline and week 4 of intervention
Change in Daily sitting time
Time Frame: Baseline and week 4 of intervention
This will be objectively measured using an activpal thigh worn activity monitor
Baseline and week 4 of intervention
Change in Daily physical activity
Time Frame: Baseline and week 4 of intervention
This will be objectively measured using an activpal thigh worn activity monitor
Baseline and week 4 of intervention
Change in Sleep quality and quantity
Time Frame: Baseline and post-intervention (within 1 week after intervention ends)
Measured with the Pittsburgh Sleep Quality Index
Baseline and post-intervention (within 1 week after intervention ends)
Change in Mental-wellbeing
Time Frame: Baseline and post-intervention (within 1 week after intervention ends)

Measured using the Warwick-Edinburgh Mental Well-being Scale. each of the following items is indicated on the following scale: none of the time=1; rarely=2; some of the time=3; often=4; all of the time=5 (5 indicating a better outcome).The total scores are summed.

Items:

  • I've been feeling optimistic about the future
  • I've been feeling useful
  • I've been feeling relaxed
  • I've been feeling interested in other people
  • I've had energy to spare
  • I've been dealing with problems well
  • I've been thinking clearly
  • I've been feeling good about myself
  • I've been feeling close to other people
  • I've been feeling confident
  • I've been able to make up my own mind about things
  • I've been feeling loved
  • I've been interested in new things
  • I've been feeling cheerful
Baseline and post-intervention (within 1 week after intervention ends)
Change in body mass index (kg/m2)
Time Frame: Baseline and post-intervention (within 1 week after intervention ends)
Calculated with measurement of height and weight
Baseline and post-intervention (within 1 week after intervention ends)
Change in waist circumference (cm)
Time Frame: Baseline and post-intervention (within 1 week after intervention ends)
Measured with a tape measure at the level of the umbillicus
Baseline and post-intervention (within 1 week after intervention ends)
Change in blood pressure (mmHg)
Time Frame: Baseline and post-intervention (within 1 week after intervention ends)
Measured using an automated blood pressure monitoring device
Baseline and post-intervention (within 1 week after intervention ends)
Change in blood glucose (mmol/L)
Time Frame: Baseline and post-intervention (within 1 week after intervention ends)
Measured via finger prick method and analysed using the Cholestech analyser
Baseline and post-intervention (within 1 week after intervention ends)
Change in triglycerides (mmol/L)
Time Frame: Baseline and post-intervention (within 1 week after intervention ends)
Measured via finger prick method and analysed using the Cholestech analyser
Baseline and post-intervention (within 1 week after intervention ends)
Change in high-density lipoprotein cholesterol (mmol/L)
Time Frame: Baseline and post-intervention (within 1 week after intervention ends)
Measured via finger prick method and analysed using the Cholestech analyser
Baseline and post-intervention (within 1 week after intervention ends)
Change in positive and negative affect
Time Frame: Baseline and post-intervention (within 1 week after intervention ends)

Measured using the positive and negative affect scale. Items will be measured on the following scale: very slightly or not at all=1; a little=2; moderately=3; quite a bit=4; extremely=5.

The items are:

  • interested
  • distressed
  • excited
  • upset
  • strong
  • guilty
  • scared
  • hostile
  • enthusiastic
  • proud
  • irritable
  • alert
  • ashamed
  • inspired
  • nervous
  • determined
  • attentive
  • jittery
  • active
  • afraid

The 10 items for POSITIVE (PA) affect are:

attentive, interested, alert, excited, enthusiastic, inspired, proud, determined, strong and active.

The 10 items for NEGATIVE (NA) affect are:

distressed, upset, hostile, irritable, scared, afraid, ashamed, guilty and nervous, jittery.

The scores generated will vary along the scale of 10 - 50, with lower scores indicating low (positive or negative) affect and higher scores indicating high (positive or negative) affect.
Baseline and post-intervention (within 1 week after intervention ends)
Change in self-efficacy
Time Frame: Baseline and post-intervention (within 1 week after intervention ends)
Measured using the Self-Efficacy Scale questionnaire (Schwarzer and Renner, 2009)
Baseline and post-intervention (within 1 week after intervention ends)
Change in job performance
Time Frame: Baseline and post-intervention (within 1 week after intervention ends)
Measured using a single-item 7-point likert scale
Baseline and post-intervention (within 1 week after intervention ends)
Change in work engagement
Time Frame: Baseline and post-intervention (within 1 week after intervention ends)
Measured using the Utrecht Work Engagement Scale multi-item 7-point likert scale
Baseline and post-intervention (within 1 week after intervention ends)
Change in musculoskeletal symptoms
Time Frame: Baseline and post-intervention (within 1 week after intervention ends)
Measured using the Sandardised Nordic Questionnaire
Baseline and post-intervention (within 1 week after intervention ends)
Change in presenteeism
Time Frame: Baseline and post-intervention (within 1 week after intervention ends)
Measured using the 8-item Work Limitations Questionnaire
Baseline and post-intervention (within 1 week after intervention ends)
Change in quality of life
Time Frame: Baseline and post-intervention (within 1 week after intervention ends)
Measured using the World Health Organization Quality of Life questionnaire
Baseline and post-intervention (within 1 week after intervention ends)
Change in perceived stress
Time Frame: Baseline and post-intervention (within 1 week after intervention ends)

Measured using the Cohen Perceived Stress likert scale.

10 items are answered on the following scale that refer to the person's thoughts and feelings over the past month: never=1; almost never=2; sometimes=3; fairly often=4; very often=5

The items are in the past month how often have you:

  • been upset because of something that happened unexpectedly
  • felt unable to control the important things in your life
  • felt nervous or stressed
  • felt confident about your ability to handle personal problems
  • felt that things were going your way
  • found that you could not cope with all the things you had to do
  • been able to control irritations in your life
  • that you were on top of things
  • been angry because of things that happened that were outside of your control
  • felt that difficulties were piling up so high that you could not overcome them

Positively worded items are reverse scored and the ratings are summed, with higher scores indicating more perceived stress.
Baseline and post-intervention (within 1 week after intervention ends)
Change in perceived vigor
Time Frame: Baseline and post-intervention (within 1 week after intervention ends)

Measured using a 12 item likert scale. The scale is: never of almost never=1; very infrequently=2; quite infrequently=3; sometimes=4; quite frequently=5; very frequently=6; always or almost always=7.

The items are based on how often have you felt this way at work? There are three subscales of the Shirom-Melamed Vigor Measure. The three subscales are: Physical Strength; Emotional Energy; and Cognitive Liveliness.

Higher scores indicate better outcomes.
Baseline and post-intervention (within 1 week after intervention ends)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
University of Bedfordshire

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Anticipated)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
March 22, 2018

Primary Completion (Anticipated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
October 30, 2018

Study Completion (Anticipated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
October 30, 2018

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
February 28, 2018

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
March 12, 2018

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
March 19, 2018

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
April 18, 2019

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
April 16, 2019

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
April 1, 2019

More Information

Terms related to this study

Keywords

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • not yet available (Other Grant/Funding Number: Laborie)

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Sedentary Lifestyle

Clinical Trials on Treadmill desk walking

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings